The biomarker analysis suggested that response to palbociclib occurred independently of tumor grade, absence of progesterone receptor (PGR) expression, or mutation in TP53, PIK3CA, or PTEN. Resistance was associated with non-luminal subtypes and persistent E2F-target gene expression [25]. Here, PGR is linked to neoplasm.